With a goal of addressing the current acute neurologist shortfall in the United States (https://ibn.fm/DrxvC), Brain Scientific (OTCQB: BRSF), a commercial-stage health care company, has developed cost-effective and portable proprietary medical devices that are positioned to disrupt the electroencephalogram (“EEG”) market.
According to a report from the American Academy of Neurology 2019 Transforming Leaders Program, nearly every U.S. state is experiencing a neurologist shortfall amid an increase in neurological disorders (https://ibn.fm/DrxvC). Experts warn that access to high-level care and diagnosis is immediately required to reduce mental disability, improve patient outcomes and increase the wellbeing of the current pool of neurologists facing quality of life issues.
As part of the effort to address the shortfall, Brain Scientific aims to support the industry with the introduction of cost-effective, disposable brain diagnostic solutions that include the NeuroCap(TM) and NeuroEEG(TM). These portable devices are part of the company’s expanded vision for neurology telemedicine, allowing practitioners to collect diagnostic information quickly, upload it to cloud-based infrastructure, and leverage artificial intelligence (“AI”) and machine learning (“ML”) algorithms to detect seizures, dementia and other brain-related conditions.
Brain Scientific’s go-to-market strategy emphasizes relationships with leading hospitals, in addition to prioritizing the creation of partnerships with industry leaders in EEG manufacturing and distribution. With an aim to further increase market penetration, the company endeavors to integrate its EEG solution with existing telemedicine platforms to serve the direct neurology market in addition to bundling its diagnostic solutions with products in related sectors to service complimentary markets.
The first phase of the company’s three-stage development process was completed in 2019 with the creation of the NeuroCap and NeuroEEG devices. Currently in its second development phase, Brain Scientific is now focused on the creation of secure cloud-based infrastructure to transmit data between neurologists and patients. The final phase, scheduled for late 2021 and 2022, will focus on the development of AI and ML functionality to provide predictive analytics that increases the diagnostic capabilities offered by its devices.
Brain Scientific’s NeuroCap and NeuroEEG devices can be used to record EEGs in settings of all types such as neurology clinics, remote clinical research labs, emergency departments, urgent care clinics, ICUs, nursing homes and assisted living facilities. With patents already approved in the United States, Europe and China, the company is positioned to dominate the market for portable brain imaging devices to address the current neurologist shortfall, improve patient outcomes and expand its vision for telemedicine in the neurology industry.
For more information on Brain Scientific Inc., visit the company’s website at www.BrainScientific.com/Invest-Now.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
David Eby, the Premier of British Columbia, has revealed that a wide range of American healthcare workers,…
Patients increasingly prefer access, speed and convenience, but healthcare systems also need better coordination, safer…
High-quality development platforms and translational research frameworks have become essential tools in rare-disease biotechnology. Soligenix…
Most existing cancer treatments not only attack cancer cells but also adversely impact healthy body cells. The…
LIXTE Biotechnology Holdings and Liora Technologies recently joined forces to soon offer a real fight…
Significant strides have been made in leveraging checkpoint inhibitor therapy to combat a number of cancers over the recent…